The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1849-1864

  Koch, Kristopher R ^a   Zhang, Chen Ou ^a   Kaczmarek, Piotr ^b   Barchi, Joseph ^b   Guo, Li ^a   Shahjee, Hanief M ^a   Keay, Susan ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiproliferative factor; Carcinoma; HB EGF; Invasion; Melanoma; MMP2

Indexed keywords

ASIALYLATED SYNTHETIC ANTIPROLIFERATIVE FACTOR DERIVATIVE; FRIZZLED PROTEIN; GELATINASE A; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CARCINOMA CELL; CELL INVASION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION; GENE MUTATION; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG CARCINOMA; MELANOMA CELL; ONCOGENE RAS; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84867774972     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9746-x     Document Type: Article

References (81)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
3. Rosenberg JE, Carroll PR, Small EJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174:14-20
4. Sengupta N, Siddiqui E, Mumtaz FH (2004) Cancers of the bladder. J R Soc Promot Health 124:228-229
5. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249. doi: 10.1016/So140-6736(09)60491-60498
6. Ward EM, Thun MJ, Hannan LM, Jemal A (2006) Interpreting cancer trends. Ann NY Acad Sci 1076:29-53
7. Miller AJ, Mihm MC Jr (2006) Mechanisms of disease: Melanoma. New Engl J Med 355:51-65
8. Thievessen I, Seifert HH, Swiatkowski S, Flori AR, Schulz WA (2003) E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 88:1932-1938
9. Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365-370
10. Berx G, Van Roy F (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3:389-393
11. Wakatsuki S, Watanabe R, Saito K, Saito T, Katagiri A, Sato S, Tomita Y (1996) Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder. Cancer Lett 103:11-17
12. Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558
13. Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305-318
14. Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12:1139-1165
15. Grant S (2008) Co-targeting survival signalling pathways in cancer. J Clin Invest 118:3003-3006
16. Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G (2009) Melanoma: molecular pathogenesis and emerging target therapies. Int J Oncol 34:1481-1489
17. Dreesen O, Brivanlou AH (2007) Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3:7-17
18. Miyamoto S, Yagi H, Yotsumoto F, Horiuchi S, Yoshizato T, Kawarabayashi T, Kuroki M, Mekada E (2007) New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res 27:3713-3721
19. Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43(Suppl):S42-S51
20. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67. doi: 10.1016/j.cell.2010.03.015
21. Sonderegger S, Haslinger P, Sabri A, Leisser C, Otten JV, Fiala C, Knöfler M (2010) Wingless (Wnt)-3A induces trophoblast migration and matrix metalloproteinase-2 secretion through canonical Wnt signaling and protein kinase B/AKT activation. Endocrinology 151:211-220
22. Razandi M, Pedram A, Park ST, Levin ER (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278:2701-2712
23. Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101:452-474
24. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S (1998) Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82:1359-1366
25. Keay SK, Szekely Z, Conrads TP, Veenstra TD, Barchi JJ Jr, Zhang C-O, Koch KR, Michejda CJ (2004) An antiproliferative factor from interstitial cystitis patients is a Frizzled 8 protein-related sialoglycopeptide. Proc Natl Acad Sci USA 101:11803-11808
26. Saitoh T, Hirai M, Katoh M (2001) Molecular cloning and characterization of human Frizzled-8 gene on chromosome 10p11.2. Int J Oncol 18:991-996
27. Rashid HH, Reeder JE, O'Connell MJ, Zhang CO, Messing EM, Keay SK (2004) Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator. BMC Urol 4:3
28. Kim J, Keay SK, Dimitrakov JD, Freeman MR (2007) p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells. FEBS Lett 581:3795-3799
29. Keay S, Seillier-Moiseiwitsch F, Zhang C-O, Chai TC, Zhang J (2003) Changes in human bladder cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiol Genomics 14:107-115
30. Shahjee H, Koch K, Guo L, Zhang C-O, Keay S (2010) Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res 29:160-170
31. Kim J, Keay SK, Freeman MR (2009) Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int 103:541-546
32. Keay S, Kleinberg M, Zhang C-O, Hise MK, Warren JW (2000) Bladder epithelial cells from interstitial cystitis patients produce an inhibitor of HB-EGF production. J Urol 164:2112-2118
33. Kaczmarek P, Keay SK, Tocci GM, Koch KR, Zhang C-O, Barchi JJ Jr, Grkovic D, Guo L, Michejda CJ (2008) Structure-activity relationship studies for the peptide portion of the bladder epithelial cell antiproliferative factor from interstitial cystitis patients. J Med Chem 51:5974-5983
34. Planey SL, Keay SK, Zhang CO, Zacharias DA (2009) Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling. Mol Biol Cell 20:1454-1463
35. Mahnken A, Kausch I, Feller AC, Kruger S (2005) E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep 14:1065-1070
36. Kashibuchi K, Tomita K, Schalken JA, Kume H, Yamaguchi T, Muto S, Horie S, Kitamura T (2006) The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49:839-845
37. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S, Taylor CR, Jones PA, Skinner DG, Cote RJ (1998) Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Instit 90:1072-1079
38. Slaton JW, Benedict WF, Dinney CP (2001) p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57:852-859
39. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E (2001) A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61:6227-6233
40. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369
41. Ching CB, Hansel DE (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 90:1406-1414
42. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G, Tan J (1994) p53 mutations in bladder carcinoma cell lines. Oncol Res 6:569-579
43. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62:6973-6980
44. Smith H, Weaver D, Barjenbruch O, Weinstein S, Ross G Jr (1989) Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder. Urology 34:193-196
45. Porta C, Figlin RA (2009) Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 182:2569-2577
46. Park JY, Lin PY, Weiss RH (2007) Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 7:863-870
47. Bjelogrlic SK, Radulovic S, Babovic N (2008) Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives. Curr Pharm Des 14:1058-1077
48. Herbst RS, Hermach JV, Lippman RM (2008) Molecular origins of cancer - lung cancer. N Engl J Med 359:1367-1380
49. Lung Carcinoma: Tumors of the Lungs. Merck manual professional edition, online edition. http://www.merck.com/mmpe/sec05/ch062/ch062b.html#sec05-ch062- ch062b-1405
50. Oren M (2003) Decision making by p53: life, death, and cancer. Cell Death Differ 10:431-442
51. Campling BG, El-Deiry WS (2003) Clinical implication of p53 mutation in lung cancer. Mol Biotech 24:141-156
52. Leinonen T, Pirinen R, Böhm J, Johansson R, Kosma VM (2008) Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 23:693-700
53. Soussi T (2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910:121-137
54. Milyavsky M, Tabach Y, Shats I, Erez N, Cohen Y, Tang X, Kalis M, Kogan I, Buganim Y, Goldfinger N, Ginsberg D, Harris CC, Domany E, Rotter V (2005) Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res 65:4530-4543. doi: 10.1158/0008-5472.CAN-04-3880
55. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274
56. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR (2000) Ras activation in human breast cancer. Breast Cancer Res Treat 62:51-62
57. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N (1993) An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 329:517-523
58. Oliveira AM, Ross JS, Fletcher JA (2005) Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124(Suppl):S16-S28
59. Jezierska A, Motyl T (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15:RA32-40
60. Hernandez-Aya LF, Gonzalez-Angulo AM (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16:404-414
61. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348-1360
62. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K (2004) Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10:2846-2850
63. Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C (2006) Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 71:61-68
64. Mihaljevic AL, Michalski CW, Friess H, Kleeff J (2010) Molecular mechanism of pancreatic cancer - understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 395:295-308
65. Baxter LL, Loftus SK, Pavan WJ (2009) Networks and pathways in pigmentation, health, and disease. Wiley Interdiscip Rev Syst Biol Med 1:359-371
66. Om A, Ghose T, Rowden G (1991) Keratin and carcinoembryonic antigen (CEA) in human melanoma cells. Virchows Arch B Cell Pathol 61:81-87
67. Selby WL, Nance KV, Park HK (1992) CEA immunoreactivity in metastatic malignant melanoma. Mod Pathol 5:415-419
68. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA (2009) Main roads to melanoma. J Translat Med 7:86-102. doi: 10.1186/1479-5876-7-86
69. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K (2001) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19:1118-1127
70. Yadav V, Denning MF (2011) Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog 50:346-352. doi: 10.1002/mc.20716
71. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ (2003) The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22:5866-5875. doi: 10.1038/sj.onc.1206699
72. Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, Morel L, Verrelle P (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 12:434-443
73. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, McKenna WG (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56:846-853
74. Krasny L, Shimony N, Tzukert K, Gorodetsky R, Lecht S, Nettelbeck DM, Haviv YS (2010) An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells. Nephrol Dial Transplant 25:373-380
75. Gottschalk AR, Doan A, Nakamura JL, Stokoe D, Haas-Kogan DA (2005) Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 63:1221-1227
76. Xia S, Yu S, Fu Q, Liu F, Zheng W, Fu X, Zhao Y (2010) Inhibiting PI3K/Akt pathway increases DNA damage of cervical carcinoma HeLa cells by drug radiosensitization. J Huazhong Univ Sci Technolog Med Sci 30:360-364
77. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4:761-767
78. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M, Rodemann HP (2008) Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7:1771-1781
79. Johnson GE, Ivanov VN, Hei TK (2008) Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 13:790-802
80. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB (1994) In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446
81. Conrads TP, Tocci GM, Hood BL, Zhang CO, Guo L, Koch KR, Michejda CJ, Veenstra TD, Keay SK (2006) CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem 281:37836-37843